Surgical Laser Market Size Analysis and Top Companies
The global surgical laser market size is estimated to hit around USD 5.76 billion by 2033 from USD 3.29 billion in 2024 with a CAGR of 6.42% from 2024 to 2033. The top companies operating in the surgical laser market are Cynosure, Inc., Lumenis Ltd., Candela Corporation, Cutera, Inc., Lutronic Corporation, El.En Group, Fotonad.o.o., Alcon, Biolase, Asclepion Laser Technologies GmbH and Others.
Market Scope
| Report Coverage |
Details |
| Market Size in 2024 |
USD 3.29 Billion |
| Market Size by 2034 |
USD 6.13 Billion |
| Growth Rate from 2024 to 2034 |
CAGR of 6.42% |
| Base Year |
2023 |
| Forecast Period |
2024 to 2034 |
| Segments Covered |
By Product Type, By Application and By End-Use |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Surgical Laser Market Companies
- Cynosure, Inc.
- Lumenis Ltd.
- Candela Corporation
- Cutera, Inc.
- Lutronic Corporation
- El.En Group
- Fotonad.o.o
- Alcon
- Biolase
- Asclepion Laser Technologies GmbH
Recent Developments
- In May 2022- RevoLix HTL, a family of pulsed and continuous wave Thulium YAG lasers that forms the basis of RevoLix Therapy for urology patients undergoing Benign Prostatic Hyperplasia (BPH) and Stone Management procedures, has been approved by the US Food and Drug Administration.
- In March 2022- The United States Food and Drug Administration granted AviClear, one of the first energy-based products to achieve this certification for the treatment of mild, moderate, and severe acne, to CUTERA, INC., a provider of dermatology solutions.
- In December 2021- The next generation PicoLO Premium Picosecond Nd:YAG Laser from LASEROPTEK Co., Ltd., a developer of top-notch laser equipment for aesthetic and medical dermatology applications, has been given FDA 510(k) clearance.
- In March 2021- Boston Scientific and a BPEA affiliate established a contract (Baring Private Equity Asia). With this agreement, Lumenis' surgical division, comprising its top-tier laser systems, will be acquired.
- In July 2019- The TempSure Firm handpiece and a small mask for SculpSure submental treatments are two new items from Hologic's Cynosure division that add to the company's expanding line of cutting-edge aesthetic treatments. The U.S. Food and Drug Administration (FDA) has officially approved SculpSure submental treatments for patients with a body mass index (BMI) of up to 49, the highest BMI clearance available for submental therapies.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
